News

Bayer Inc. announced that Health Canada approved finerenone, under the brand name KERENDIA, as an adjunct to standard of care therapy in adults with chronic kidney disease (CKD) and…
Read More...

Normunity, Inc., a biotechnology company creating novel precision anti-cancer immunotherapies, announced its launch and Series A financing of $65 million. The Series A was led by Canaan…
Read More...

SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure across the globe, announced that the Company made a new…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved TECVAYLI (teclistamab-cqyv) for the treatment of adult…
Read More...

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced a strategic…
Read More...

BioMed X announced the launch of their first joint research project with Sanofi. As part of this, a new research group to be established at the BioMed X Institute in Heidelberg,…
Read More...

AstraZeneca’s Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma…
Read More...

Astellas Pharma Inc. and Taysha Gene Therapies, Inc. announced a strategic investment to support the advancement of Taysha's adeno-associated virus (AAV) gene therapy development…
Read More...

Daiichi Sankyo received notification of acceptance by the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) of quizartinib in combination with standard…
Read More...

Kite, a Gilead Company and Refuge Biotechnologies, Inc. announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for…
Read More...

ARS Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review ARS’ New Drug Application (NDA) for neffy for the emergency treatment…
Read More...

Sumitovant Biopharma Ltd. in conjunction with parent company Sumitomo Pharma Co., Ltd. and Myovant Sciences announced today that they have entered into a definitive agreement pursuant…
Read More...

AbbVie announces that the U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of adults with active…
Read More...

HOOKIPA Pharma Inc. a company developing a new class of immunotherapies based on its proprietary arenavirus platform, announced a strategic collaboration and license agreement with…
Read More...

Corium, LLC a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Gurnet Point Capital (“Gurnet Point”), a…
Read More...

Takeda, Zedira and Dr. Falk Pharma GmbH announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac…
Read More...

Amgen announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc., a biopharmaceutical company focused on orally administered therapeutics to…
Read More...

AbbVie announced the acquisition of DJS Antibodies Ltd ("DJS"), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target…
Read More...

Novavax, Inc. announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373) has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to…
Read More...

Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple…
Read More...